Literature DB >> 22488172

Prognostic value of nuclear matrix protein expression in localized prostate cancer.

Francesco Ricci1, Alessandra Rubagotti, Linda Zinoli, Rosa Mangerini, Pier Vitale Nuzzo, Giorgio Carmignani, Alchiede Simonato, Paola Barboro, Cecilia Balbi, Francesco Boccardo.   

Abstract

PURPOSE: The aim of the study was to correlate nuclear matrix (NM) protein expression profiles with the risk of PSA progression or death in early prostate cancer (PCa).
METHODS: High-resolution two-dimensional gel electrophoresis (2D-PAGE) was used to identify tumor-associated NM proteins in the PCa specimens obtained from 94 patients. The association between the expression of each protein and the probability of PSA progression or death was studied through univariate analysis. Unsupervised hierarchical clustering analysis was then used to generate patient clusters showing comparable outcomes by including the proteins that were predictive at univariate analysis. PSA-free and overall survival curves relative to each cluster were constructed by means of the Kaplan-Meier method and curves compared by the log-rank test. Multi-parametric models were constructed according to Cox proportional hazard technique.
RESULTS: After a median follow-up of 11.7 years (range, 6.5-16.2), 50 patients progressed and 22 died. Of the eight NM proteins identified through 2D-PAGE, proteins NM-6, NM-7 and NM-8 were confirmed to be individually associated with a higher risk of PSA progression at univariate analysis. Proteins NM-6 and NM-8 were also predictive of survival probability. Hierarchical clustering analysis of these proteins allowed to identify one cluster of tumors co-expressing the three proteins or proteins NM-6 and NM-8, characterized by a very poor outcome, suggesting a specific role for these proteins in PCa progression. The predictive value of this mini-signature in respect to PSA-free survival was confirmed by multivariate analysis.
CONCLUSIONS: Changes in NM scaffolding are strongly associated with the clinical outcome of patients following radical prostatectomy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22488172     DOI: 10.1007/s00432-012-1216-0

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  19 in total

Review 1.  Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999.

Authors:  D G Bostwick; D J Grignon; M E Hammond; M B Amin; M Cohen; D Crawford; M Gospadarowicz; R S Kaplan; D S Miller; R Montironi; T F Pajak; A Pollack; J R Srigley; J W Yarbro
Journal:  Arch Pathol Lab Med       Date:  2000-07       Impact factor: 5.534

Review 2.  Nuclear matrix protein expression in prostate cancer: possible prognostic and diagnostic applications.

Authors:  Paola Barboro; Alessandra Rubagotti; Francesco Boccardo; Barbara Carnemolla; Cristina Darrigo; Eligio Patrone; Cecilia Balbi
Journal:  Anticancer Res       Date:  2005 Nov-Dec       Impact factor: 2.480

Review 3.  Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies.

Authors:  Rodolfo Montironi; Roberta Mazzuccheli; Marina Scarpelli; Antonio Lopez-Beltran; Giovanni Fellegara; Ferran Algaba
Journal:  BJU Int       Date:  2005-06       Impact factor: 5.588

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

5.  Nuclear matrix proteins changes in cancerous prostate tissues and their prognostic value in clinically localized prostate cancer.

Authors:  Francesco Boccardo; Alessandra Rubagotti; Giorgio Carmignani; Andrea Romagnoli; Guido Nicolò; Paola Barboro; Silvio Parodi; Eligio Patrone; Cecilia Balbi
Journal:  Prostate       Date:  2003-06-01       Impact factor: 4.104

6.  Percentage carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues.

Authors:  P A Humphrey; R T Vollmer
Journal:  Mod Pathol       Date:  1997-04       Impact factor: 7.842

7.  Heterogeneous ribonucleoprotein k and thymidine phosphorylase are independent prognostic and therapeutic markers for nasopharyngeal carcinoma.

Authors:  Lih-Chyang Chen; Chuen Hsueh; Ngan-Ming Tsang; Ying Liang; Kai-Ping Chang; Sheng-Po Hao; Jau-Song Yu; Yu-Sun Chang
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

8.  Heterogeneous nuclear ribonucleoprotein K is a novel regulator of androgen receptor translation.

Authors:  Nishit K Mukhopadhyay; Jayoung Kim; Bekir Cinar; Aruna Ramachandran; Martin H Hager; Dolores Di Vizio; Rosalyn M Adam; Mark A Rubin; Pradip Raychaudhuri; Arrigo De Benedetti; Michael R Freeman
Journal:  Cancer Res       Date:  2009-03-03       Impact factor: 12.701

9.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1976-12       Impact factor: 7.640

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  2 in total

1.  Prognostic value of stromal and epithelial periostin expression in human prostate cancer: correlation with clinical pathological features and the risk of biochemical relapse or death.

Authors:  Pier Vitale Nuzzo; Alessandra Rubagotti; Linda Zinoli; Francesco Ricci; Sandra Salvi; Simona Boccardo; Francesco Boccardo
Journal:  BMC Cancer       Date:  2012-12-28       Impact factor: 4.430

2.  Androgen receptor activity is affected by both nuclear matrix localization and the phosphorylation status of the heterogeneous nuclear ribonucleoprotein K in anti-androgen-treated LNCaP cells.

Authors:  Paola Barboro; Luana Borzì; Erica Repaci; Nicoletta Ferrari; Cecilia Balbi
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.